About Salix Pharmaceuticals
Salix Pharmaceuticals is a Healthcare company based in Bridgewater (United States) founded in 1989, and was acquired by Bausch Health in February 2015. Specialty pharmaceutical company focusing on prevention and treatment of gastrointestinal (GI) disorders. Salix Pharmaceuticals has completed 2 acquisitions, including Oceana Therapeutics and Santarus. Its website salix.com draws about 16 thousand monthly visits. Salix Pharmaceuticals offers products and services including GI Treatments and Therapeutic Pipeline. Its focus areas include Diversified Pharmaceuticals.
Company details
Salix Pharmaceuticals is a specialty pharmaceutical company It is involved in licensing, developing, and marketing products to treat gastroenterology disorders. It has a portfolio of 21 products markets its product line through dedicated, specialty sales groups to U.S. healthcare providers in the areas of gastroenterology, hepatology, colorectal surgery, endocrinology, internal medicine, primary care, infectious disease, allergyimmunology, and pediatric urology. It has also acquired companies like Santarus and Ocean Therapeutics before getting acquired by Valeant Pharmaceuticals on April 1, 2015
- Headquarters Bridgewater, United States
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website salix.com
- Social LinkedIn X
- Acquired by Bausch Health (Feb 2015)
- Annual Revenue$1.13 B (USD)24as on Dec 31, 2014
- Net Profit-$414.91 M (USD)-417as on Dec 31, 2014
- EBITDA-$490.1 M (USD)-294as on Dec 31, 2014
- Latest Funding Round$750M (USD), Debt – Conventional
Dec 2013
- InvestorsBausch Health
& 3 more
- Investments & AcquisitionsOceana Therapeutics
& 1 more
- Acquired by
Products & Services of Salix Pharmaceuticals
Salix Pharmaceuticals offers a comprehensive portfolio of products and services, including GI Treatments and Therapeutic Pipeline.
Medications addressing gastrointestinal diseases and patient needs.
Innovative products for advancing GI healthcare solutions.
Funding Insights of Salix Pharmaceuticals
- Total Rounds 4
- Last Round Debt – Conventional — $750M
- First Round $345M
(Jun 1999)
- Investors Count 2
All 4 funding rounds of Salix Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2013 | $750M | Debt – Conventional | – | – | – |
| Nov 2013 | $750M | Debt – Conventional | – | – | – |
| May 2001 | $28M | Post-IPO | – | – | |
| Jun 1999 | $345M | Debt – Convertible | – | – | – |
4 investors in total: 4 institutional.
Investors in Salix Pharmaceuticals
Salix Pharmaceuticals has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Bausch Health, Tellabs and Franklin Street Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth-stage healthcare companies are invested in by EW Healthcare Partners. | ewhealthcare.com | New York, United States | ||
Investment consulting services are provided to clients by the firm. | 1990 | franklin-street.com | Chapel Hill, United States | |
End-to-end network access solutions are provided to telecom providers. | 1978 | tellabs.com | Naperville, United States | |
Therapeutics for multiple diseases including dermatology and neurology are developed. | 1960 | bauschhealth.com | Laval, Canada |
Investor details for Salix Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Salix Pharmaceuticals
210 people are tracked at Salix Pharmaceuticals (23 in leadership, 187 in team).
| Name | Role | Group |
|---|---|---|
Christopher Allen | Senior Director, Medical Affairs | Leadership |
Todd Brouillette | Regional Sales Director | Leadership |
Thomas D'Alonzo | CEO / President | Leadership |
Lara Abdo | Senior Director, Marketing, US Brand Lead | Leadership |
Fouad Kouch | Senior Regional Sales Director | Leadership |
Brent Williams | Director, Commercial Analytics | Leadership |
Christine Trucco | Director Of Digital Strategy | Leadership |
Adam Derbyshire | CFO | Leadership |
Scott Leonard | Senior Director Of Marketing | Leadership |
Deepshikha Shekhawat | Associate Director | Leadership |
Michael Mohan | Senior Sales Director | Leadership |
Chad Miller | Executive Director, Marketing | Leadership |
Kate Kim | Director, Medical Affairs - MSL East Region | Leadership |
Orit Faiman | Associate Director Medical Affairs | Leadership |
Tim Reilly | Senior Sales Director | Leadership |
David Bloom | Associate Director, Medical Affairs | Leadership |
Bobbie Sue Brown | Associate Director Medical Affairs | Leadership |
Melissa Christy | Senior National Sales Director | Leadership |
Patricia Halton | Associate Director | Leadership |
Scott Vedepo | Sr. Sales Director - Gastroenterology | Hepatology | Institutions, Salix Pharmaceuticals | Leadership |
190 more people are available in the full profile.
Complete people profiles for Salix Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Salix Pharmaceuticals
Salix Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Oceana Therapeutics and Santarus.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Proprietary biopharmaceutical products for gastrointestinal and metabolic conditions are commercialized. | santarus.com | San Diego, United States | 1996 | Nov 2013 | $2.6B | |
Therapeutics are developed for colorectal, gastroenterology, and urological diseases. | oceanathera.com | Edison, United States | 2008 | Nov 2011 | $300M |
Complete acquisition details for Salix Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Salix Pharmaceuticals
8 dated milestones of Salix Pharmaceuticals across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Salix Pharmaceuticals is founded.
- Funding First funding round of $345.0M.
- Exit Acquired by Tellabs.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Oceana Therapeutics.
- Acquisition Acquires Santarus.
- Funding Latest funding round, Debt – Conventional, of $750.0M.
- Exit Acquired by Bausch Health.
Web traffic of Salix Pharmaceuticals
The website of Salix Pharmaceuticals (salix.com) receives about 15.6K visits a month and ranks #1,433,848 among all websites worldwide, #1,860 in Biotechnology and Pharmaceuticals.
- Monthly visits15.6K
▼ 22.8% vs previous month
- Unique visitors10.5K
per month
- Global rank#1,433,848
among all websites
- Category rank#1,860
Health · Biotechnology and Pharmaceuticals
- Bounce rate58%
- Pages per visit1.4
- Average visit1 min 34 sec
- DevicesDesktop 15% · Mobile 85%
Websites whose visitors overlap most with Salix Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| maynepharma.com | 100% | 18.6K | #918,677 | View details | |
| medpharm.com | 99% | 5.3K | #6,145,162 | View details | |
| indivior.com | 98% | 33.3K | #1,007,938 | View details | |
| pfizer.com | 97% | 1.9M | #24,984 | View details | |
| sunovion.com | 83% | 11.4K | #4,229,536 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 33 similar websites and full traffic analytics for Salix Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 33 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Salix Pharmaceuticals (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Salix Pharmaceuticals
Complete news archive for Salix Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Salix Pharmaceuticals
Salix Pharmaceuticals was founded in 1989 and raised its 1st funding round 10 years after it was founded.
Salix Pharmaceuticals is headquartered in Bridgewater, United States. It is registered at Bridgewater, New Jersey, United States.
Annual revenue of Salix Pharmaceuticals is $1.13B as on Dec 31, 2014.
Salix Pharmaceuticals is a specialty pharmaceutical company It is involved in licensing, developing, and marketing products to treat gastroenterology disorders. It has a portfolio of 21 products markets its product line through dedicated, specialty sales groups to U.S. healthcare providers in the areas of gastroenterology, hepatology, colorectal surgery, endocrinology, internal medicine, primary care, infectious disease, allergyimmunology, and pediatric urology. It has also acquired companies like Santarus and Ocean Therapeutics before getting acquired by Valeant Pharmaceuticals on April 1, 2015.
Salix Pharmaceuticals offers GI Treatments and Therapeutic Pipeline.
Salix Pharmaceuticals has made 2 acquisitions, including Oceana Therapeutics, and Santarus.
Salix Pharmaceuticals has 4 investors. Key investors include Bausch Health, Tellabs, Franklin Street Partners, and EW Healthcare Partners.
Yes. Salix Pharmaceuticals was acquired by Bausch Health in February 2015.